Wikipedia

Lerdelimumab

Lerdelimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetTGF beta 2
Clinical data
ATC code
  • none
Legal status
Legal status
  • Development discontinued
Identifiers
CAS Number
ChemSpider
  • none
UNII
(verify)

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.

It was being developed to reduce scarring after glaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results for that condition.[2]

References

  1. ^ "Lerdelimumab". Drugs in R&D. 3 (2): 106–8. 1 February 2002. doi:10.2165/00126839-200203020-00006. PMID 12001808.
  2. ^ "CAT abandons Trabio after second clinical trial failure". The Pharma Letter. 28 March 2005.
This article is copied from an article on Wikipedia® - the free encyclopedia created and edited by its online user community. The text was not checked or edited by anyone on our staff. Although the vast majority of Wikipedia® encyclopedia articles provide accurate and timely information, please do not assume the accuracy of any particular article. This article is distributed under the terms of GNU Free Documentation License.

Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.